Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach

The lung cancer stem cell (LuCSC) model comprises an attractive framework to explore acquired drug resistance in non-small cell lung cancer (NSCLC) treatment. Here, we used NSCLC cell line model to translate cellular heterogeneity into tractable populations to understand the origin of lung cancers a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Zhiguang, Sperl, Bianca, Gärtner, Silvia, Nedelko, Tatiana, Stacher-Priehse, Elvira, Ullrich, Axel, Knyazev, Pjotr G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493460/
https://www.ncbi.nlm.nih.gov/pubmed/31069016
http://dx.doi.org/10.18632/oncotarget.26817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493460/
https://www.ncbi.nlm.nih.gov/pubmed/31069016
http://dx.doi.org/10.18632/oncotarget.26817

Ejemplares similares